文献速递癫痫

癫痫医保受益人品牌药与仿制药使用及总处方费用的变化

Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy.
PubMed 文献 · Neurology · 2022-08-22

该回顾性队列研究基于2008至2018年20%随机医保样本,分析癫痫患者抗癫痫发作药物(ASM)的处方趋势与费用。结果显示品牌药、第一代及酶诱导型ASM的用药天数占比均下降,但品牌药费用在2010年后因拉考沙胺使用增加及单药日费用上涨而显著上升。2018年品牌药仅占用药天数的14%,却占费用的79%。

要点

  • 2008至2018年,品牌药用药天数占比从56%降至14%,第一代ASM从55%降至32%,酶诱导型ASM从44%降至24%。
  • 最常用ASM由2008年的苯妥英(25%)变为2018年的左乙拉西坦(27%)。
  • 2018年品牌药占费用79%但仅占用药天数14%,品牌药一年供应费用上涨277%,仿制药下降42%。

核心结论

  • 2008至2018年第一代及酶诱导型ASM使用减少;品牌药ASM初始减少带来费用降低,但2010年后因拉考沙胺使用增加及品牌药单药日费用上涨277%而显著增加。
  • 品牌药ASM占处方少数但占费用多数。

研究设计与样本

  • 回顾性队列研究,纳入2008至2018年20%随机医保样本中具有癫痫诊断及ASM处方且连续参加按服务收费(A、B、D部分)的受益人。
  • 每年癫痫受益人数量为77,000至133,000例。
  • 按人年汇总每种ASM的用药天数及费用(调整至2018年美元),并将ASM分为品牌药与仿制药、第一代与新一代、酶诱导型与非酶诱导型。

主要发现

  • 最常见ASM从2008年的苯妥英(25%)变为2018年的左乙拉西坦(27%);2008年左乙拉西坦为14%,2018年苯妥英为9%。
  • 品牌药(2008年56% vs 2018年14%)、第一代(2008年55% vs 2018年32%)及酶诱导型ASM(2008年44% vs 2018年24%)占用药天数的比例均随时间下降。
  • 每人年品牌药用药天数初始下降(2008年250天;2009年121天;2010年96天),后趋于平稳(2013至2018年间为66至69天),与拉考沙胺每人用药天数显著增加有关(2008年0天;2018年20天)。
  • 2018年品牌药ASM占费用的79%,但仅占用药天数的14%;品牌药一年供应费用上涨277%,仿制药下降42%(2008年品牌药约2800美元 vs 仿制药约800美元;2018年品牌药约10700美元 vs 仿制药约460美元),许多常用品牌药ASM每用药日费用约为其仿制药等效品的10倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: To characterize trends in antiseizure medication (ASM) fills and total prescription costs in people with epilepsy. METHODS: This was a retrospective cohort study of beneficiaries with epilepsy (ASM, plus ICD codes) in a 20% random Medicare sample, with continuous Fee-For-Service coverage (Parts A, B, and D) in 2008-2018. We summed the number of pill days and costs (adjusted to 2018 dollars) per person-year for each ASM. ASMs were categorized into brand vs generic, first vs newer generation, and enzyme inducers vs noninducers. RESULTS: There were 77,000-133,000 beneficiaries with epilepsy per year. The most common ASM was phenytoin in 2008, which shifted to levetiracetam in 2018 (2008: phenytoin 25%, levetiracetam 14%; 2018: phenytoin 9%, levetiracetam 27%). Brand name (2008: 56%; 2018: 14%), first-generation (2008: 55%; 2018: 32%), and enzyme-inducing ASMs (2008: 44%; 2018: 24%) each decreased over time as a proportion of pill days. The number of brand pill days per person-year initially decreased (e.g., 2008: 250; 2009: 121; 2010: 96) but then plateaued (2013-2018: between 66 and 69) given a notable increase in lacosamide pill days per person (2008: 0; 2018: 20). Total brand name costs per year initially decreased 2008-2010 (2008: $150 million; 2010: $72 million) but then increased after 2010 (2018: $256 million). In 2018, brand name ASMs represented 79% of costs despite representing only 14% of pill days, a 1-year pill supply became 277% more expensive for brand name medications but 42% less expensive for generic medications over time (2008: brand ∼$2,800 vs generic ∼$800; 2018: brand ∼$10,700 vs generic ∼$460), and many common brand name ASMs cost approximately 10-fold more per pill day than their generic equivalents. DISCUSSION: First-generation and enzyme-inducing ASMs waned from 2008 to 2018. Although brand name ASMs initially waned translating into lower costs and potentially higher value care, after 2010, brand name costs markedly increased because of increasing use of lacosamide plus a 277% increase in per-pill cost of brand name ASMs. Brand name ASMs represented a minority of prescriptions, but the majority of costs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Terman SW, Lin CC, Kerr WT, et al. Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy. Neurology. 2022. PMID: 35705496. doi:10.1212/WNL.0000000000200779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。